Skip to main content
Genor Biopharma Holdings Limited logo

Genor Biopharma Holdings Limited — Investor Relations & Filings

Ticker · 6998 ISIN · KYG3807B1007 LEI · 254900QMR54NB8I3GG47 HKEX Manufacturing
Open in API
Filings indexed 421 across all filing types
Latest filing 2026-05-13 Board/Management Inform…
Country KY Cayman Islands
Listing HKEX 6998

About Genor Biopharma Holdings Limited

https://www.eddingpharm.com

Genor Biopharma Holdings Limited is an innovation-driven biopharmaceutical company focused on the discovery, research, development, and commercialization of human biological pharmaceutical products. The company primarily targets oncology and autoimmune diseases, with an expanding pipeline covering cardiovascular, respiratory, and anti-infective fields. Genor operates a full value chain encompassing R&D, world-class manufacturing, and a robust commercialization network. A key strategic element is the integration of technology and AI into its drug development platform to accelerate clinical-stage therapies. While rooted in China, the company actively pursues global cooperation, in-licensing, and the development of commercial capabilities in overseas mainstream markets to deliver innovative treatments to patients globally.

Recent filings

Filing Released Lang Actions
CHANGE OF JOINT COMPANY SECRETARY
Board/Management Information Classification · 94% confidence The document is an official announcement on the Hong Kong Exchange regarding the resignation and appointment of the joint company secretary, a senior management position. It outlines changes in company secretarial roles and a waiver application to the Stock Exchange. There are no financial statements, earnings data, or request for votes. This clearly falls under a Board/Management Information announcement regarding changes in senior management.
2026-05-13 English
Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 30 April 2026
Regulatory Filings Classification · 95% confidence The document is a detailed monthly return filed with the Hong Kong Exchanges and Clearing Limited (HKEX) regarding movements in securities for the issuer Edding Genor Group Holdings Limited. It includes detailed data on authorized share capital, issued shares, treasury shares, share options, repurchases, and confirmations related to public float sufficiency. The document is a regulatory submission reporting share capital movements and related confirmations, not a financial report, earnings release, or management discussion. It is not an announcement of a report but a regulatory filing itself. The form code FF301 and the nature of the content align with regulatory filings related to share capital movements under HKEX rules. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length and detail support a high confidence score.
2026-05-07 English
VOLUNTARY ANNOUNCEMENT - LATEST UPDATE ON COOPERATION WITH CANDID THERAPEUTICS
Capital/Financing Update Classification · 95% confidence The document is a voluntary announcement by Edding Genor Group Holdings Limited regarding a business cooperation update with Candid Therapeutics, including details of license agreements, equity participation, milestone payments, and a pending acquisition by Union Chimique Belge. It is an announcement of a business development and transaction update rather than a full financial report or regulatory filing. The document length is 4287 characters, which is relatively short and consistent with an announcement rather than a detailed report. There is no detailed financial data, no audit information, no earnings summary, no management discussion, or other report content. The content focuses on a corporate transaction and business cooperation update, which fits best under Capital/Financing Update (CAP) as it involves licensing agreements, equity participation, and acquisition terms. It is not a merger filing (MA) or takeover bid (TAR) form but a voluntary announcement of a financing and cooperation update. Therefore, the most appropriate classification is CAP with high confidence.
2026-05-04 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 95% confidence The document is a Next Day Disclosure Return related to changes in issued shares or treasury shares, including share buybacks and on-market sales of treasury shares. It contains detailed information about share repurchases, including dates, prices, and quantities, as well as confirmations of compliance with listing rules. The document is regulatory in nature, reporting specific transactions in the company's own shares rather than announcing a new share issue or capital change. It is not a general regulatory announcement or a report publication announcement. The content fits the definition of a Transaction in Own Shares (POS) filing, which covers reports of the company buying back or selling its own shares (share repurchase/issuance). The document length and detail confirm it is the report itself, not just an announcement or certification. Therefore, the correct classification is POS with high confidence.
2026-04-30 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 96% confidence The document is an HKEx ‘‘Next Day Disclosure Return’’ (Form FF305) detailing changes in issued shares and treasury shares, including a repurchase of 1,000,000 shares held as treasury shares under Main Board/GEM rules. It provides complete repurchase report data (dates, number of shares repurchased, prices, aggregate amounts) and confirmations by the issuer’s officers. This is not a general Annual or Interim Report, nor a simple announcement of publication. It specifically reports on the company's own share repurchase activity, matching the definition of a Transaction in Own Shares (code POS).
2026-04-29 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 98% confidence The document is a Next Day Disclosure Return (Form FF305) filed under Hong Kong Stock Exchange rules, detailing changes in issued shares and treasury shares, including share repurchases and on-market sales of treasury shares. This is a direct company report of buying back its own shares, matching the definition of “Transaction in Own Shares” (POS).
2026-04-28 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.